Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis ; day:8 ; month:2 ; year:2020 ; pages:1-11
Journal of neurology ; (8.2.2020), 1-11
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-019-09690-6
- URN
-
urn:nbn:de:101:1-2020050521582915527796
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schweitzer, F.
- Laurent, S.
- Fink, G. R.
- Barnett, Michael H.
- Hartung, Hans-Peter
- Warnke, C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
Current Disease-Modifying Therapies in Multiple Sclerosis
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
Current Disease-Modifying Therapies in Multiple Sclerosis
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions